Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. - Wikidata - awgldk - TriplyDB

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

http://www.wikidata.org/entity/Q36399234

about

Radiotherapy combination opportunities leveraging immunity for the next oncology practice Principles of antibody-mediated TNF receptor activation ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis Cellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.NKG2A inhibits invariant NKT cell activation in hepatic injury.Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.CD1d-based combination therapy eradicates established tumors in mice.CD1d activation and blockade: a new antitumor strategy TRAIL in cancer therapy: present and future challenges.Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis.Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis.Interleukin-2 rescues helpless effector CD8+ T cells by diminishing the susceptibility to TRAIL mediated death.Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases Detection of Anticancer and Apoptotic Effect of the Produced IgYs against the Three Extracellular Domain of Human DR5 Protein.Targeted ovarian cancer treatment: the TRAILs of resistance.TRAIL and its receptors as targets for cancer therapy.Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer.Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement Recent developments in cancer chemotherapy oriented towards new targets.TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma.Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain.TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response From cancer immunosurveillance to cancer immunotherapy.Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance

P2860

Q26738443-4AFB6A92-C6C5-4975-9327-610DF2F1846A Q26796270-3A27C328-9255-49BC-9BAD-9CDC7DAD9D7C Q28386923-B6652D9A-24BE-4EA0-92D3-22471E348363 Q28540934-8DBD8E3E-C4B7-404F-85F0-A112ED5D89B7 Q33502208-6B6D20F2-099F-4AB8-929C-1A815F9435A7 Q33559627-CEFF3049-7D10-4F7F-88FC-9FD99820FBEA Q33726537-3D22E728-8A4E-4BB4-B4D8-00770B602C4B Q33739557-37741754-B5A9-4FBE-9108-49033925C5FE Q33863928-5A0D7DDF-62A8-4FF6-8161-822525D70115 Q33991741-1E0B5417-9B42-4DEB-B3B4-1EA6EE5212ED Q33999606-F7B3EF39-0E79-495A-9BD1-591950B717D0 Q34132999-38D7306C-3D3C-4C58-BC21-60A05234FF72 Q34257887-7254E6E3-4D8E-47F8-9237-1A8142B32F3E Q34257902-38F90501-BE2F-45D7-8143-B498BF999BE5 Q34291312-51D1F92E-E175-455A-8818-16B2386F042F Q34610496-49BFD8E4-815F-4BB7-8333-94085E5D7093 Q34809370-7973659C-63DD-415E-9A12-1450F4CA48C1 Q34876724-5B028ED2-17D5-44F8-A001-D3952BEEFD9F Q35136775-F1E63170-C502-42B8-AEF2-5741947E7521 Q35157433-C0CBFB21-73B4-4B47-8566-C63DD0503B36 Q35172090-0162583D-2020-4ED9-BDA4-397B33249BEE Q35543789-F319EC91-BE86-4CDC-9BEE-2A1F5E09909B Q35609438-CC3E26CD-0B1E-4CDD-9C5F-30AFDFB12E80 Q35927476-6F0D9CB0-A3E1-4944-A451-A4B7744BA8CE Q36066311-19FCDE4D-4A1C-465B-9CC8-0CB2639FCA3E Q36070101-8F3501BA-0BFB-42E3-992F-302E056D7E82 Q36079365-1876963B-88DD-421E-B7BE-01E63C3020F5 Q36150860-4D9DFC77-095F-439E-8C7D-02963A540C3D Q36365504-1BE11EFA-FE2B-4A7E-B7AE-80774F35A701 Q36456479-96F98E66-6650-434D-8B4D-C83020F2948F Q36470781-BDA3B1A3-0AF4-49C9-A500-B4947EA09D2E Q36491838-2FB84546-BA17-4445-A40E-20E1BC4880E4 Q36731174-210998BD-4DA6-4666-89D9-C7E3DC450A09 Q36825315-F83FB8B1-D0CC-4393-89ED-447A1EB97C43 Q36837553-00F22572-A33A-460C-946E-6239447330CA Q36846723-8B224647-D346-475F-AA35-148A8568EB48 Q36936587-BD1503CB-A33E-4984-93BF-413F9D18022E Q36945070-0CB79A27-F3A3-4429-9108-E39982AC0FDD Q36990588-E5756229-7DC4-406B-96D2-7661CAF3AAD5 Q37021699-0363E337-E9D4-4C56-B1FA-7C18E4FAF7DC

P2860

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

http://www.wikidata.org/entity/Q36399234

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

@ast

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

@en

type

label

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

@ast

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

@en

prefLabel

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

@ast

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

@en

P1433

Q36399234-9FFADE2A-013B-4E10-91A0-0395D90D0F83

P1476

Q36399234-1A7A9DAE-C5AC-4018-98B9-52C7F7AA281F

P2093

Q36399234-27545139-E342-4063-B5FE-0F7DDDE79867

Q36399234-2BB56796-012A-4481-8D7E-98ECCAE429D9

Q36399234-470BA7C8-8578-47BB-ABF6-29A21EFB8239

Q36399234-5DC3B217-F114-4553-BDB8-9111F5532AED

Q36399234-5E7EDFB7-98DA-4617-958C-CE5414C34650

Q36399234-6ECB3F2F-3707-4A54-B753-41A7C0572B44

Q36399234-88C56B20-B77A-4AC2-AAD8-1AE4A7B17B39

Q36399234-991D9805-F421-4AA0-B8D1-F6727874434B

Q36399234-B1FFBDCA-E3D7-446B-AB85-E11453C7C3C4

P2860

Q36399234-02F39ED3-E62F-461E-ADD6-E36716A5552E

Q36399234-042FE575-99AA-49CC-B9C2-427EEE924896

Q36399234-09900F65-09CD-488C-878D-6750C0C1A1F3

Q36399234-19806C6A-D620-4843-99C0-102D08DF4CBC

Q36399234-1EF6DEA1-E4AA-4F31-9E60-57AA1E041085

Q36399234-21C4AC57-764A-4F9B-8CBF-FC4C80174796

Q36399234-245135E3-0C1A-4024-A55B-9B8129E7195E

Q36399234-2700087B-A804-4743-A5ED-874E3840A8BF

Q36399234-2AA3E525-22E4-42CC-BF53-08DA6EBAC18F

Q36399234-2C610914-1627-427D-9ED6-97851C6B3C42

P304

Q36399234-F3A28129-7CF1-4627-BE72-638A23A8FAD2

P31

Q36399234-3908BF54-F3FC-428F-9310-65B5D4F5F6E0

P356

Q36399234-3A81A457-FC28-43B2-9F92-AAE45195FAB3

P407

Q36399234-260466D4-DCD1-4554-9814-A7F8EBCCE58E

P433

Q36399234-C643D830-26EB-4A1B-A302-263141E5EB1C

P478

Q36399234-7BC297D2-6EAC-4E81-8B53-A5807BCF1F3D

P50

Q36399234-36376141-A23B-4F0B-AA27-D0DF43C56EF0

Q36399234-B0449131-8A28-4ED4-B1D3-6943174D3BBE

P577

Q36399234-C63333A3-F0D4-45A6-839F-DEA00FDDB782

P5875

Q36399234-1DE4FF1A-937A-4BE4-A78E-14500212EAB1

P698

Q36399234-5CC2CFDC-1BA2-4D87-94A2-96B2EA5A3820

P921

Q36399234-420D0431-722C-4E53-AEC5-F4174EC0A94A

P932

Q36399234-EC9BFE29-9A50-44C8-8922-835BC7A5CCF3

P356

P1433

Journal of Experimental Medicine

P1476

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

@en

P2093

Hisaya Akiba

http://www.w3.org/2001/XMLSchema#string

Jane E Tanner

http://www.w3.org/2001/XMLSchema#string

Kazuyoshi Takeda

http://www.w3.org/2001/XMLSchema#string

Ko Okumura

http://www.w3.org/2001/XMLSchema#string

Naoko Seki

http://www.w3.org/2001/XMLSchema#string

Noriko Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Thomas J Sayers

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Hayakawa

http://www.w3.org/2001/XMLSchema#string

Yuko Kojima

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotherapy: past, present and future

Inhibition of death receptor signals by cellular FLIP

Identification and characterization of a new member of the TNF family that induces apoptosis

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Improving the efficacy of antibody-based cancer therapies

Regulation of immune responses by TGF-beta

Apoptosis by death factor

Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

P304

437-448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20031457

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

199

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8880099

http://www.w3.org/2001/XMLSchema#string

P698

14769851

http://www.w3.org/2001/XMLSchema#string

P921

P932

2211825

http://www.w3.org/2001/XMLSchema#string